Next Article in Journal
The Response Regulator VC1795 of Vibrio Pathogenicity Island-2 Contributes to Intestinal Colonization by Vibrio cholerae
Next Article in Special Issue
Bioactive-Glass-Based Materials with Possible Application in Diabetic Wound Healing: A Systematic Review
Previous Article in Journal
Ryanodine Receptor Staining Identifies Viable Cardiomyocytes in Human and Rabbit Cardiac Tissue Slices
Previous Article in Special Issue
Efficient Recovery Strategy of Luteolin from Agricultural Waste Peanut Shells and Activity Evaluation of Its Functional Biomolecules
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 24
Issue 17
10.3390/ijms241713522
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synergistic Effect, Improved Cell Selectivity, and Elucidating the Action Mechanism of Antimicrobial Peptide YS12

by
Suzia Aktar Suchi
1,†,
Dae Young Lee
2,†,
Young Kyun Kim
1,
Seong Soo Kang
3,
Tahmina Bilkis
4 and
Jin Cheol Yoo
1,*
1
Department of Pharmacy, College of Pharmacy, Chosun University, Gwangju 61452, Republic of Korea
2
Department of Herbal Crop Research, National Institute of Horticultural and Herbal Science, RDA, Eumseong 27709, Republic of Korea
3
Department of Veterinary Medicine and BK21 Four Program, Chonnam National University, Gwangju 61186, Republic of Korea
4
Department of Biomedical Sciences, Chosun University, Gwangju 61452, Republic of Korea
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Int. J. Mol. Sci. 2023, 24(17), 13522; https://doi.org/10.3390/ijms241713522
Submission received: 6 June 2023 / Revised: 15 August 2023 / Accepted: 25 August 2023 / Published: 31 August 2023
(This article belongs to the Special Issue The Advances in Antimicrobial Biomaterials)
Browse Figures
Versions Notes

Abstract

:
Antimicrobial peptides (AMPs) have attracted considerable attention as potential substitutes for traditional antibiotics. In our previous research, a novel antimicrobial peptide YS12 derived from the Bacillus velezensis strain showed broad-spectrum antimicrobial activity against Gram-positive and Gram-negative bacteria. In this study, the fractional inhibitory concentration index (FICI) indicated that combining YS12 with commercial antibiotics produced a synergistic effect. Following these findings, the combination of YS12 with an antibiotic resulted in a faster killing effect against bacterial strains compared to the treatment with the peptide YS12 or antibiotic alone. The peptide YS12 maintained its antimicrobial activity under different physiological salts (Na+, Mg2+, and Fe3+). Most importantly, YS12 exhibited no cytotoxicity towards Raw 264.7 cells and showed low hemolytic activity, whereas positive control melittin indicated extremely high toxicity. In terms of mode of action, we found that peptide YS12 was able to bind with LPS through electrostatic interaction. The results from fluorescent measurement revealed that peptide YS12 damaged the integrity of the bacterial membrane. Confocal laser microscopy further confirmed that the localization of peptide YS12 was almost in the cytoplasm of the cells. Peptide YS12 also exhibited anti-inflammatory activity by reducing the release of LPS-induced pro-inflammatory mediators such as TNF-α, IL-1β, and NO. Collectively, these properties strongly suggest that the antimicrobial peptide YS12 may be a promising candidate for treating microbial infections and inflammation.

1. Introduction

Nowadays, the widespread use of antibiotics causes the emergence of drug-resistant bacteria, which is now a major public health threat [1,2]. Different pathogenic microorganisms emerge quickly, and the rate of development of new antibiotics is slower, which ultimately results in antibiotic resistance [3]. The scientific world has devoted a great effort to find new, safer, and more effective antimicrobial agents from natural sources including plants, animals, microorganisms, etc. [4,5]. One of the most prominent classes of antibacterial agents from natural sources is antimicrobial peptides (AMPs).
Antimicrobial peptides (AMPs) are typically cationic and usually composed of less than 50 amino acids [6]. AMPs are considered promising therapeutic agents due to their broad antimicrobial spectrum and unique mode of action against bacteria [7,8]. Unlike conventional antibiotics, positively charged AMPs are believed to exhibit electrostatic interaction with negatively charged bacterial membranes. Lipopolysaccharide (LPS) and lipoteichoic acid (LTA) are the major cell membrane components appearing in Gram-negative and Gram-positive bacteria. Several widely accepted models explain the antimicrobial mechanism of AMPs, including the barrel-stave model, toroidal model, or detergent-like action (carpet model) [9,10]. Most AMPs exert antimicrobial mechanisms by disrupting or permeabilizing bacterial membranes [11]. Moreover, AMPs also show various intracellular mechanisms against bacteria, including inhibiting DNA, RNA, and protein synthesis.
However, Gram-negative organisms release Lipopolysaccharide (LPS; endotoxin), which has been identified as a significant inflammatory trigger, and an uncontrolled LPS response contributes to the risk of localized inflammation [12]. Several proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-1 β (IL-1β), and nitric oxide (NO) play a significant role in mediating inflammation. Recent studies have shown that many peptides efficaciously suppress the production of LPS-induced NO and cellular cytokines [13].
Despite the early promise of AMPs as alternatives to antibiotics, many AMPs are not suitable for therapeutic applications due to their high manufacturing cost, ease of degradability, high hemolytic activities, and high cytotoxicity. Another significant barrier to AMPs as therapeutics is their sensitivity to physiological salts. To overcome these limitations, short AMPs isolated from natural sources have been identified as less toxic, with high stability and low production cost [14].
In the previous study, a novel antimicrobial peptide named YS12 was isolated from the traditional Korean food kimchi. Peptide YS12 from Bacillus velezensis CBSYS12 showed antimicrobial activity against different multi-drug resistant bacteria [15]. In many studies, it has been suggested that AMPs in combination with antibiotics offer rapid bactericidal effects and lower the chance of pathogens developing resistance [16,17]. In the current investigation, we aimed to show the synergistic effect of peptide YS12 with commercial antibiotics using combinational therapy. Next, we confirmed that peptide YS12 maintained antimicrobial activity in the presence of different physiological salts. Meanwhile, cytotoxicity towards mouse macrophage Raw 264.7 cell and hemolytic activities of peptide YS12 were also measured compared with the standard well-known antimicrobial compound melittin. The present work also explored the underlying mechanism of antimicrobial peptide YS12 on different bacteria. In the initial stage of peptide–microbial membrane interaction, peptide YS12 was found to bind with LPS. Thereafter, we assessed the inner membrane permeability of peptide YS12 using fluorescent dye PI and ONPG against bacterial strains. Confocal laser microscopy was used to observe the localization of the peptide YS12 on the bacterial cell membrane. Finally, the anti-inflammatory effect of peptide YS12 was also investigated on LPS-stimulated murine macrophage RAW264.7 cells in vitro.

2. Results and Discussion

2.1. MIC of Peptide YS12 and Antibiotics against Different Bacterial Strains

The infections caused by different microbes significantly increased over time [18]. Specifically, Gram-negative bacteria (E. coli, P. aeruginosa) and Gram-positive bacteria (S. aureus) are the most common bacterium causing various severe infectious diseases. Table 1, presents the Minimum Inhibitory Concentration (MIC) of peptide YS12 and antibiotics against different bacterial strains. The data indicated that peptide YS12 showed prominent antimicrobial activity at MIC values of (6–12 µg/mL) against the isolated Gram-negative strains. The bacterial strain E. coli KCTC 1923 had a lower MIC value of 12 µg/mL to ciprofloxacin and 24 µg/mL to oxacillin against P. aeruginosa KCTC 1637. However, erythromycin and oxacillin showed MIC values higher than 96 µg/mL against P. aeruginosa and S. aureus KCTC 1928 strains, respectively.

2.2. Synergism Effect of Peptide YS12 with Conventional Antibiotics

Combined antibiotic therapy is considered a promising approach to combat bacteria and increase the potency of antibiotics. Specifically, combining AMPs with antibiotics has drawn attention as it often shows a stronger killing effect against bacteria [19]. In the above study, we aimed to determine the synergistic effect between peptide YS12 and antibiotics, including oxacillin, ciprofloxacin, or erythromycin by calculating the fractional inhibitory concentration index (FICI) against E. coli KCTC 1923, P. aeruginosa KCTC 1637 and S. aureus KCTC 1928. In Table 2, a significant synergistic effect was obtained for YS12 and ciprofloxacin against E. coli KCTC 1923, which achieved a fractional inhibitory concentration index (FICI) of 0.157. Similarly, combining peptide YS12 with oxacillin or erythromycin exhibited a synergistic effect (FICI of 0.325 to 0.415) on E. coli and S. aureus strains. The partial synergism (FICI > 0.5) was observed when YS12 was combined with ciprofloxacin or erythromycin against P. aeruginosa and S. aureus, respectively. Moreover, peptide YS12 combined with erythromycin showed additive or partial synergism (FICI of 1.00) against P. aeruginosa. The overall finding of this study proved that the peptide YS12 exhibited a strong synergistic effect with conventional antibiotics against different pathogenic strains.
After that, we observed the intense synergistic effect of peptide YS12 combined with the commercial antibiotic using the time-killing test. We evaluated the bactericidal effect of peptide YS12 with oxacillin against E. coli, and P. aeruginosa bacteria. Peptide YS12 and oxacillin showed a killing effect on both bacterial strains over 180 min. In Figure 1a, the data indicated that combining peptide YS12 with oxacillin at the concentration of 2 × MIC showed a rapid bactericidal effect. E. coli cells were completely killed within only 60 min. P. aeruginosa was slightly less sensitive compared to E. coli. In P. aeruginosa, the combination of peptide YS12 and oxacillin at 2 × MIC resulted in the reduction in the CFU from 5.3 logs to 2.4 logs at 60 min and destroyed the cell bacterial cells in 90 min (Figure 1b). These findings confirmed that the peptide YS12 with the antibiotic showed a faster killing effect than using the peptide YS12 or the antibiotic itself. Some studies also revealed the synergistic effect between AMPs and antibiotics [20]. The results suggested that combination therapy using AMPs and antibiotics may be an effective strategy to combat bacteria.

2.3. Stability Assay

A significant limitation of natural antimicrobial peptides (AMPs) is their possible degradation by different physiological concentrations of salts [21]. AMPs may exhibit a partial or even total loss of antimicrobial activity under different salt concentrations [22]. AMPs must maintain antimicrobial activities in salt-containing environments to be effective therapeutic agents. Numerous studies have suggested that monovalent Na+, Mg2+, and Fe3+ may reduce the antimicrobial activity of naturally occurring AMPs [23]. Therefore, we determined the antimicrobial activity of peptide YS12 and melittin using different physiological salt concentrations. As shown in Table 3, the peptide YS12 had a minimal effect on Na+, Mg2+, and Fe3+ cations against bacterial strains. The peptide YS12 maintained antimicrobial activity (MIC~2 µg/mL) against E. coli and P. aeruginosa in the presence of Na+ and Fe3+, respectively. Similarly, for S. aureus, YS12 retained its stability (MIC~2–4 µg/mL) at various salt concentrations. The peptide YS12 showed a comparatively higher MIC value (4–8 µg/mL) against E. coli and P. aeruginosa in the presence of Mg2+. According to our findings, the peptide YS12 proved to have a strong tolerance to different salts. These results are consistent with the outcomes of salt stability studies from various AMPs [24,25].

2.4. Cytotoxicity and Hemolytic Activity of YS12

It has been assumed that AMPs exhibit considerable cell selectivity. Cytotoxicity and hemolytic activities are frequently determined to assess the cellular toxicity of AMPs [26]. To evaluate the cell selectivity more clearly, we checked the cytotoxicity of peptide YS12 on Raw 264.7 cells using the MTT reagent. According to the findings (Figure 2a), no cytotoxicity was observed up to 40 µg/mL in Raw 264.7 macrophage cells. Cell viability for YS12 was measured at approximately 83% at 120 µg/mL. Interestingly, the peptide YS12 caused great survival in Raw 264.7 cells. The hemolytic activity of peptide YS12 was also checked using red sheep blood. In Figure 2b, the peptide YS12 exhibited less than 15% hemolysis at the highest (150 µg/mL) concentration. In contrast, melittin was used as a negative control and demonstrated 76% hemolytic activity at 100 µg/mL. The low cytotoxic and hemolytic effects of AMPs were also reported in other studies [27,28].

2.5. The Potential Antimicrobial Peptide Mechanisms of Peptide YS12

2.5.1. Liposome Preparation and Aggregation

LUVs are widely employed to mimic bacterial membranes [29]. The lipid bilayer of the microbial membrane is composed of phospholipids containing phosphoglycerol (PG), phosphoethanolamine (PE), phosphatidylcholine (PC), and cardiolipin that have negative charges. To investigate the interaction between peptide YS12 and bacterial membrane, we established different types of LUVs with PE: PG (7:3, w/w), PG, and PC, respectively [30]. The amount of aggregation caused by the peptide YS12 was measured using the turbidity of liposomes. PE: PG liposome suspension turbidity increased gradually and consistently at a peptide/lipid (P/L) ratio from 0.05 to 0.025. When the peptide/liposome ratio was 0.025, the turbidity was achieved at 0.025, as shown in Figure 3a. With increased peptide/liposome ratios, the turbidity of PG arises slowly compared with PE: PG. However, the peptide could not interrupt phosphatidylcholine (PC) liposomes. The stronger interactions of the peptide YS12 with bacterial membranes were confirmed through the aggregation of PE: PG and PG liposomes. AMPs were also shown to have an impact on bacterial membranes [31].

2.5.2. LPS Binding Affinity of Peptide YS12

Gram-positive and Gram-negative bacterial membranes differ significantly in their molecular components and structure. The interaction between bacterial membranes and AMPs plays a vital role in microbial killing and developing new antimicrobial agents [32,33]. Typically, LPS acts as a barrier in Gram-negative organisms. We initially evaluated the binding affinity of peptide YS12 for bacterial endotoxin (LPS). The peptide YS12 could bind with LPS by electrostatic attraction to the E. coli surface. In Figure 3b, it was observed that LPS only slightly decreased the antibacterial activity of YS12 at lower concentrations of 5 µg/mL, but at 80 µg/mL, LPS successfully neutralized the bactericidal activity of YS12. Polymyxin B, an effective outer membrane binding agent, was employed as a positive control, and the bacteria was no longer sensitive at 80 µg/mL. Ampicillin as negative control also did not affect LPS. Based on the findings, YS12 seems to have a strong affinity for the LPS of Gram-negative bacteria.
We also conducted the dansyl-polymyxin B displacement experiment to quantify the LPS binding affinity of peptide YS12. DPX works effectively as an indicator for cationic bindings on both purified LPS and whole bacterial cells [34]. However, DPX is nonfluorescent in free solution but exhibits high fluorescence when bound with LPS [35]. As seen in Figure 4a, peptide YS12 was bound to LPS by replacing the dansyl PMB and decreased fluorescence from 90% to 40% at 2.5 and 40 µg/mL, respectively. The peptide YS12 exerted an electrostatic interaction with LPS that contributed to its excellent antimicrobial activity against Gram-negative bacteria. Additionally, we evaluated the LPS neutralization activity of peptide YS12 using a Limulus amebocyte lysate (LAL) test. Different concentrations of YS12 (2.5–40 µg/mL) and 1 ng/mL LPS were employed. In Figure 4b, we found that peptide YS12 neutralized LPS in a dose-dependent manner and showed 78% neutralization at the maximum concentration of 40 µg/mL. These results indicated that the peptide YS12 showed significant effects on LPS. Numerous studies have shown that AMPs have a higher affinity for binding LPS to Gram-negative bacteria [36].

2.5.3. Peptide YS12 Damaged the Membrane Integrity of Bacteria

The positively charged AMPs have different mechanisms of action on bacteria, including disruption of the integrity of the cell membrane and leakage of intracellular material [37,38]. Initially, we confirmed that the peptide YS12 showed an excellent LPS binding affinity on the Gram-negative strain. In this study, we explored the effects of peptide YS12 on the inner membrane of bacterial strains (E. coli, P. aeruginosa) employing the fluorescent dye PI. Typically, the peptide treatment allowed PI to enter into bacterial cells [39]. In Figure 5a,b, it was shown that the presence of peptide YS12 at 1×, 2×, and 4 × MIC increased fluorescence intensity over time. The peptide YS12 exhibited the highest fluorescence of approximately 75% and 71% at 4 × MIC against E. coli and S. aureus, respectively. The result indicated that the peptide YS12 had an impact on the integrity of the bacterial cell membrane.
Moreover, a colorimetric and spectrophotometric substrate (ONPG) is usually used to measure the β-galactosidase activity in the inner membrane. To assess the effect of peptide YS12 on the inner membrane of E. coli, ONPG was used as β-galactosidase. The bacterial cytoplasmic membrane consists of negatively charged hydroxyl phospho-lipids, which facilitate the binding of cationic AMPs [40]. In Figure 5c, peptide YS12 caused rapid permeabilization of the E. coli membrane. The fluorescence intensity was gradually increased in a time- and concentration-dependent manner. The experimental results using PI and ONPG demonstrated that the peptide YS12 affected the integrity of the bacterial inner membrane, which ultimately led to cell death. Furthermore, by measuring the release of calcein from negatively charged liposomes, the membrane permeabilization capability of peptide YS12 was also detected. Peptide YS12 resulted in membrane disruption by inducing over 80% calcein leakage from calcein-loaded liposomes at the highest concentration of 4 × MIC (Figure 5d). Collectively, our results revealed that the peptide YS12 damaged the bacterial membrane by increasing PI intake, cytoplasmic-galactosidase release, and calcein release. These results would provide a better understanding of the mechanism of action of antimicrobial peptides (AMPs). Other studies also suggested that the antimicrobial peptides (AMPs) treatment enhanced bacterial membrane destruction [41,42].

2.5.4. Confocal Microscopy

In this study, we employed Fluorescein isothiocyanate (FITC)-labeled YS12 dye to investigate the entrance of the peptide YS12 into bacterial cells. Peptide localization on bacterial cells was visualized using confocal laser microscopy. FITC-labeled YS12 corresponding to a 4 × MIC or 24 µg/mL and 4 × MIC or 48 µg/mL value was applied on P. aeruginosa KCTC 1637 and E. coli KCTC 1923 strains, respectively, for 30 min. In Figure 6a,b, we observed that FITC-labeled YS12 translocated into the bacterial cell by aggregating in the cytoplasm. The results of this study proved that peptide YS12 accumulated in the cytoplasm of the cells.

2.6. The Ability of Peptide YS12 to Inhibit Pro-Inflammatory Mediators in RAW 264.7 Cells

AMPs possess remarkable anti-inflammatory effects by neutralizing LPS [43]. In bacterial infections, proinflammatory cytokines such as TNF-α and IL-1β are generated more readily, and excessive cytokines can induce organ damage and inflammation. We evaluated the effect of peptide YS12 on the secretion of LPS-stimulated cytokines (TNF-α, IL-1β) and NO in Raw 264.67 cells. The cells were treated with LPS (1 µg/mL) and peptide YS12 at a concentration of 10–40 µg/mL. The ELISA kit was used to measure TNF-α release. In Figure 7a, peptide YS12 showed a considerable effect on NO production in a concentration-dependent manner. In Figure 7b,c, we observed that peptide YS12 led to a significant reduction in the release of pro-inflammatory mediators, including TNF-α and IL-1β. Taken together, these results suggest that peptide YS12 may be an effective approach for developing a new anti-inflammatory agent.

3. Materials and Method

3.1. Materials and Reagents

Materials were obtained in the following manner: the strain CBSYS12 was isolated from the Korean traditional food kimchi; and PG (L-alpha-phosphatidyl glycerol), (PE) phosphatidylethanolamine, and PC (l-alpha-phosphatidylcholine) were acquired from Avanti polar Lipid (Alabaster, AL, USA). The following reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA): LPS (from E. coli), MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide), Polymyxin B, and propidium iodide (PI). From commercial sources, other chemical reagents of analytical grade were obtained.

3.2. Peptide YS12 Production and Purification

The production and purification of the antimicrobial peptide YS12 derived from Bacillus velezensis CBSYS12 was described in our previous paper [15].

3.3. Antimicrobial Activity Determination in Terms of MIC

The concentration that suppressed bacterial growth was identified using a minimum inhibitory concentration (MIC) assay described in our recently published paper [15].

3.4. Synergistic Effect of the Peptide with Different Antibiotics

The synergistic effects of peptide YS12 with other conventional antibiotics were investigated using the two-dimensional checkerboard method [44]. Peptide YS12 was added with serially diluted antibiotics into 96-well plates. Then, bacterial cells (approximately 106 microorganisms) were mixed into each plate, and growth-control wells were filled with only the medium. OD600 was measured by a spectrophotometer after 18 h of incubation at 37 °C. The fractional inhibitory concentration (FIC) index was obtained using the following equation:
FIC index = FICA + FICB
[(MIC of drug A in combination/MIC of drug A alone) + (MIC of drug B in combination/MIC of drug B alone)]
FIC index was represented as follows: FICI ≤ 0.5 indicated synergy and 0.5 < FICI ≤ 1 denoted partial synergism.

3.5. The Time-Dependent Killing of the Synergistic Group

Combination therapy against the Gram-negative strains E. coli and P. aeruginosa was used to analyze the synergistic effect of peptide YS12 with the commercial antibiotic oxacillin [45]. Peptide YS12 at the concentration of 2 × MIC was mixed with the 2 × MIC of oxacillin. At different time intervals (30, 60, 90, 120, 150, and 180 min), the mixture was collected and put onto MHB agar plates. The bactericidal effect was determined by colony-forming units (CFUs). The experiment was also carried out without using antibiotics as the control.

3.6. Stability Assay

The stability assay was performed to determine the antimicrobial activity of peptide YS12 against different physiological salts following the previous article [46]. In Mueller Hinton Broth media, E. coli KCTC 1923, P. aeruginosa KCTC 1637, and S. aureus KCTC 1928 strains were grown and diluted to 2 × 105 CFU/mL. The bacterial suspensions were incubated with peptide YS12 supplemented with different physiological salts, such as NaCl (100 mM, 150 mM), MgCl2 (0.5 mM, 1 mM), and FeCl3 (2 µM, 4 µM). To determine MIC, the experiment was carried out according to the method previously explained [15].

3.7. In Vitro Cytotoxicity Assay

The cytotoxicity of peptide YS12 was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) reagent in Raw 264.7 cells [47]. In brief, Raw 264.7 cells were cultivated in a 96-well plate. The cells were incubated at 37 °C with 5% CO2 overnight. The cells were treated with increasing concentrations (5–120 µg/mL) of peptide for 24 h at 37 °C under 5% CO2 atmosphere. MTT was added to the well the next day at a 0.5 mg/mL concentration. The absorbance was monitored at 570 nm using an ELISHA reader (Molecular Devices, Sunnyvale, CA, USA). At least two replicates were given to each measurement.

3.8. Hemolytic Activity of YS12

The hemolytic activity of peptide YS12 using fresh red sheep blood was measured as previously reported with slight alteration [48]. Fresh red sheep blood cells were washed with PBS, and the supernatants were removed by centrifugation at 1000× g for 5 min. The peptide YS12 at 5–150 µg/mL was added to 96 well plates. Melittin was used as a control. A quantity of 4% RBC was put into each well and incubated at 37 °C. At 1000× g, the plate was again centrifuged for 5 min at 4 °C, and the supernatants were placed on a fresh 96-well plate. The optical density (OD) at a wavelength of 414 nm was measured using a microplate reader (Bio-Tek Instruments, Winooski, VT, USA). The absorbance of PBS-treated cells indicated zero hemolysis, while those treated with 0.1% Triton X-100 indicated complete hemolysis.
The hemolysis percentage was calculated using the formula shown below:
Hemolysis (%) = (Abssample − AbsPBS)/(Abstriton − AbsPBS) × 100

3.9. The Potential Antimicrobial Mechanisms Study of Peptide YS12

3.9.1. Preparation and Aggregation of Liposomes

Large unilamellar vesicles (LUVs) were developed using the freeze-thaw technique [49]. The liposome mixture was prepared by dissolving PE: PG (7:3, w/w), PG, and PC in chloroform. The dispersed liposomes were then removed with argon gas. The lipid film was dried, and then the solution was vortexed in PBS with a pH of 7.2 until a milky appearance developed in the suspension. LUVs were created utilizing freeze-thaw cycles under a water bath and liquid nitrogen. A polycarbonate membrane with a thickness of 0.2 m was used to extrude the suspensions. The peptide YS12 was added at 5, 10, 20, and 40 µg/mL to 400 µM LUVs composed of PE: PG, PG, and PC. Using a microplate reader, the enhanced absorbance was determined at 405 nm.

3.9.2. Effect of Lipopolysaccharides (LPS)

The mechanism of action of AMPs is greatly dependent on their binding capability with the cell membrane [50]. The antibacterial activity of peptide YS12 against E. coli KCTC 1923 in the presence of LPS was identified. E. coli cells (approximately 6.0 × 107 CFU/mL) were grown and diluted with tryptic soy broth. The cell suspension was mixed with lipopolysaccharides from E. coli O111: B at a concentration of 5, 10, 40, or 80 µg/mL. Peptide YS12 was added to a final concentration (25 µg/mL) against E. coli. Ampicillin at 10 µg/mL and Polymyxin at 5 µg/mL were used as positive and negative controls, respectively. The mixtures were incubated at 37 °C for 60 min. The stayer cells were measured by spreading tryptic soy agar.

3.9.3. LPS Binding Assay Using Dansyl-Polymyxin B

A Danyl-polymyxin B displacement experiment was also carried out to determine the binding affinity of peptide YS12 for LPS [51]. LPS from E. coli and Danyl-polymyxin B were treated with pH 7.2 HEPES buffer (1 mL; 5 mM) to achieve optimal fluorescence. The peptide YS12 was added to the cuvette, and a spectrometer was used to measure the decrease in fluorescence. Excitation and emission wavelengths of the fluorescence were detected at 340 nm and 485 nm, respectively.

3.9.4. Neutralization of LPS by Peptide

A chromogenic limulus amebocyte lysate assay was used to measure the LPS neutralization [52]. The peptide YS12 (5–40 µg/mL) and constant concentration of LPS (from E. coli) (1 ng/mL) were put in the pyrogenic sterile microtiter plate and incubated at 37 °C. The solutions were mixed and treated with equivalent amounts of Limulus amebocyte lysate reagent for 10 min. Following the addition of a chromogenic substrate solution, a yellow color appeared. An amount of 25% acetic acid was added to terminate the reaction, and the absorbance was measured at 580 nm.

3.9.5. PI Uptake Assay

Membrane permeabilization assay of peptide YS12 was performed using fluorescent dye propidium iodide (PI) [53]. Briefly stated, E. coli and S. aureus bacteria were grown in MHB medium to the mid-log phase and diluted in sodium phosphate buffer (10 mM) to an OD600 value of 0.25. On a dark 96-well plate, each bacterium was treated with PI (final concentration, 20 µM). After mixing, peptide YS12 at 1×, 2×, and 4 × MIC was added to each well. The fluorescence spectrophotometer was used to measure the absorbance at 580 nm and 620 nm for the excitation and emission, respectively, and the percentage (%) of fluorescence intensity obtained from the peptide YS12 was represented relative to untreated controls.

3.9.6. Inner Membrane Permeability Activity

Ortho-nitrophenyl-galactose (ONPG) was used to analyze the inner membrane permeabilization of the peptide YS12 against E. coli bacteria [54]. Bacterial cells were cultivated, collected, and resuspended in PBS (pH 7.2) to a final OD420 of 1.2. The peptide (1×, 2×, 4 × MIC) and ONPG (final concentration 1.5 mM) were placed on 96 well plates. The microplate reader was then used to measure the absorbance at 420 nm.

3.9.7. Calcein Dye Leakage Assay

Calcein-loaded liposomes were prepared to imitate bacterial membranes. The liposomes were formed according to the method described in the earlier report [55]. Peptide YS12 at 1 × MIC, 2 × MIC, and 4 × MIC was loaded into liposomes (1:1, v/v). The fluorescence intensity (excitation 490 nm, emission 530 nm) was recorded at 0, 5, 10, 15, 20, and 25 min. The calcein release rate was calculated by the following equation:
The extent of calcein output was calculated as
(Ft − F0)/(Fmax − F0),
where Ft represents the fluorescence of a peptide liposome/calcein solution at a particular time, and F0 and Fmax indicate the initial fluorescence. Ft is the fluorescence of a peptide liposome/calcein solution at the time, and F0 and Fmax are the initial fluorescence and the fluorescence following total liposomal disruption by the detergent (Triton X-100, 10% w/w), respectively.

3.9.8. Confocal Microscopy

Gram-negative strains E. coli and P. aeruginosa were grown in LB broth to the mid-logarithmic phase. The cell suspensions were centrifuged and washed several times with a 10 mM PBS buffer (pH 7.5). The cells were treated with fluorescein isothiocyanate (FITC) labeled peptide YS12 (4 × MIC) at 37 °C. After an hour of incubation, the cells were centrifuged, pipetted into PBS buffer (pH 7.5), and then allowed to stand on a glass slide. Cell images with FITC-labeled peptides were observed using confocal laser microscopy (LSM 510, Carl Zeiss, Jena, Germany).

3.10. Inhibitory Effect of Peptide YS12 on the Production of Proinflammatory Mediators in LPS-Stimulated Raw 264.7 Cells

The anti-inflammatory effect of peptide YS12 was also investigated on LPS-stimulated murine macrophage RAW264.7 cells [56]. RAW264.7 (1 × 105) cells were seeded in a 96-well culture plate overnight in triplicate. Cells were exposed to peptide samples (10, 20, and 40 µg/mL) and then stimulated with 1µg/mL of LPS purified from E. coli 0111:B4 (Sigma-Aldrich, St. Louis, MO, USA) for 16 h. After incubation, equal volumes of supernatant fractions and Griess reagent (1% sulfanilamide, 0.1% naphthyl ethylenediamine dihydrochloride, and 2% phosphoric acid) were mixed and incubated for 10 min. After incubation, the fluorescence was measured. Moreover, the inhibitory effect of peptide YS12 on the release of inflammatory cytokines such as TNF-α, and IL-1β was determined by ELISA. Raw 264.7 cells were incubated with peptide YS12 at 10–40 µg/mL and LPS (1 µg/mL) for 24 h. After incubation, the supernatants were measured for TNF-α, and IL-1β by ELISA.

3.11. Statistical Analysis

The average and standard deviation (SD) of the experimental data were represented by three replications per inspection. Graph Pad Prism software, version 5, was used to complete the statistical investigation.

4. Conclusions

In our previous study, we evaluated the antimicrobial activity of peptide YS12 against both Gram-positive and Gram-negative strains. In our present work, peptide YS12 showed a synergistic effect with commercial antibiotics. Enhanced salt-resistant properties and low cytotoxicity of peptide YS12 were also observed. In terms of mode of action, peptide YS12 exhibited direct antimicrobial activity by disrupting the integrity of the bacterial cell membrane. Additionally, peptide YS12 exerted potent anti-inflammatory activities. Based on the overall findings, we assume that peptide YS12 may be used as a promising candidate for treating infectious illnesses caused by drug-resistant strains and inflammation-related disorders.

Author Contributions

Conceptualization, S.A.S., Y.K.K. and D.Y.L.; methodology, S.A.S., Y.K.K. and D.Y.L.; validation, S.S.K., T.B. and J.C.Y.; formal analysis, S.S.K.; resources and data analysis, T.B.; writing—original draft preparation, S.A.S. and Y.K.K.; writing—review and editing, D.Y.L. and J.C.Y.; supervision, J.C.Y.; funding acquisition, J.C.Y. All authors have read and agreed to the published version of the manuscript.

Funding

This work was carried out with the support of the National Research Foundation of Korea (NRF) grant funded by the Korean government (MEST) (NRF-2018R1D1A1B05050137).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are available on request from the corresponding author.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Ventola, C.L. The Antibiotic Resistance Crisis: Part 1: Causes and threats. Pharm. Ther. 2015, 40, 277–283. [Google Scholar]
  2. Serwecińska, L. Antimicrobials and Antibiotic-Resistant Bacteria: A Risk to the Environment and to Public Health. Water 2020, 12, 3313. [Google Scholar] [CrossRef]
  3. Sifri, Z.; Chokshi, A.; Cennimo, D.; Horng, H. Global contributors to antibiotic resistance. J. Glob. Infect. Dis. 2019, 11, 36–42. [Google Scholar] [CrossRef]
  4. Kesharwani, P.; Chopra, S.; Dasgupta, A. (Eds.) Drug Discovery Targeting Drug-Resistant Bacteria; Academic Press: Cambridge, MA, USA, 2020. [Google Scholar]
  5. Jampilek, J. Design and Discovery of New Antibacterial Agents: Advances, Perspectives, Challenges. Curr. Med. Chem. 2018, 25, 4972–5006. [Google Scholar] [CrossRef] [PubMed]
  6. Izadpanah, A.; Gallo, R.L. Antimicrobial peptides. J. Am. Acad. Dermatol. 2005, 3, 381–390. [Google Scholar] [CrossRef]
  7. Portelinha, J.; Duay, S.S.; Yu, S.I.; Heilemann, K.; Libardo, M.D.J.; Juliano, S.A.; Klassen, J.L.; Angeles-Boza, A.M. Antimicrobial Peptides and Copper(II) Ions: Novel Therapeutic Opportunities. Chem. Rev. 2021, 121, 2648–2712. [Google Scholar] [CrossRef]
  8. Cruz, J.; Ortiz, C.; Guzmán, F.; Fernández-Lafuente, R.; Torres, R. Antimicrobial Peptides: Promising Compounds against Pathogenic Microorganisms. Curr. Med. Chem. 2014, 21, 2299–2321. [Google Scholar] [CrossRef]
  9. Nguyen, L.T.; Haney, E.F.; Vogel, H.J. The expanding scope of antimicrobial peptide structures and their modes of action. Trends Biotechnol. 2011, 29, 464–472. [Google Scholar] [CrossRef]
  10. Malanovic, N.; Lohner, K. Antimicrobial Peptides Targeting Gram-Positive Bacteria. Pharmaceuticals 2016, 9, 59. [Google Scholar] [CrossRef]
  11. Wang, J.; Dou, X.; Song, J.; Lyu, Y.; Zhu, X.; Xu, L.; Li, W.; Shan, A. Antimicrobial peptides: Promising alternatives in the post feeding antibiotic era. Med. Res. Rev. 2019, 39, 831–859. [Google Scholar] [CrossRef]
  12. Marshall, J.C. Lipopolysaccharide: An endotoxin or an exogenous hormone? Clin. Infect. Dis. 2005, 41, S470–S480. [Google Scholar] [CrossRef]
  13. Haskó, G.; Szabó, C.; Németh, Z.H.; Kvetan, V.; Pastores, S.M.; Vizi, E.S. Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J. Immunol. 1996, 157, 4634–4640. [Google Scholar] [CrossRef] [PubMed]
  14. Mahlapuu, M.; Håkansson, J.; Ringstad, L.; Björn, C. Antimicrobial Peptides: An Emerging Category of Therapeutic Agents. Front. Cell. Infect. Microbiol. 2016, 6, 194. [Google Scholar] [CrossRef] [PubMed]
  15. Suchi, S.A.; Bin Nam, K.; Kim, Y.K.; Tarek, H.; Yoo, J.C. A novel antimicrobial peptide YS12 isolated from Bacillus velezensis CBSYS12 exerts anti-biofilm properties against drug-resistant bacteria. Bioprocess Biosyst. Eng. 2023, 46, 813–828. [Google Scholar] [CrossRef] [PubMed]
  16. Allahverdiyev, A.M.; Kon, K.V.; Abamor, E.S.; Bagirova, M.; Rafailovich, M. Coping with antibiotic resistance: Combining nanoparticles with antibiotics and other antimicrobial agents. Expert Rev. Anti-Infect. Ther. 2011, 9, 1035–1052. [Google Scholar] [CrossRef] [PubMed]
  17. León-Buitimea, A.; Garza-Cárdenas, C.R.; Garza-Cervantes, J.A.; Lerma-Escalera, J.A.; Morones-Ramírez, J.R. The demand for new antibiotics: Antimicrobial peptides, nanoparticles, and combinatorial therapies as future strategies in antibacterial agent design. Front Microbiol. 2020, 11, 1669. [Google Scholar] [CrossRef]
  18. Jones, K.E.; Patel, N.G.; Levy, M.A.; Storeygard, A.; Balk, D.; Gittleman, J.L.; Daszak, P. Global trends in emerging infectious diseases. Nature 2008, 451, 990–993. [Google Scholar] [CrossRef]
  19. Dosler, S.; Mataraci, E. In vitro pharmacokinetics of antimicrobial cationic peptides alone and in combination with antibiotics against methicillin resistant Staphylococcus aureus biofilms. Peptides 2013, 49, 53–58. [Google Scholar] [CrossRef]
  20. Feng, Q.; Huang, Y.; Chen, M.; Li, G.; Chen, Y. Functional synergy of α-helical antimicrobial peptides and traditional antibiotics against Gram-negative and Gram-positive bacteria in vitro and in vivo. Eur. J. Clin. Microbiol. Infect. Dis. 2015, 34, 197–204. [Google Scholar] [CrossRef]
  21. Ong, Z.Y.; Wiradharma, N.; Yang, Y.Y. Strategies employed in the design and optimization of synthetic antimicrobial peptide amphiphiles with enhanced therapeutic potentials. Adv. Drug Deliv. Rev. 2014, 78, 28–45. [Google Scholar] [CrossRef]
  22. Kang, H.-K.; Kim, C.; Seo, C.H.; Park, Y. The therapeutic applications of antimicrobial peptides (AMPs): A patent review. J. Microbiol. 2017, 55, 1–12. [Google Scholar] [CrossRef] [PubMed]
  23. Zhu, X.; Zhang, L.; Wang, J.; Ma, Z.; Xu, W.; Li, J.; Shan, A. Characterization of antimicrobial activity and mechanisms of low amphipathic peptides with different α-helical propensity. Acta Biomater. 2015, 18, 155–167. [Google Scholar] [CrossRef]
  24. Kim, E.Y.; Rajasekaran, G.; Shin, S.Y. LL-37-derived short antimicrobial peptide KR-12-a5 and its d-amino acid substituted analogs with cell selectivity, anti-biofilm activity, synergistic effect with conventional antibiotics, and anti-inflammatory activity. Eur. J. Med. Chem. 2017, 136, 428–441. [Google Scholar] [CrossRef]
  25. Chou, S.; Shao, C.; Wang, J.; Shan, A.; Xu, L.; Dong, N.; Li, Z. Short, multiple-stranded β-hairpin peptides have antimicrobial potency with high selectivity and salt resistance. Acta Biomater. 2016, 30, 78–93. [Google Scholar] [CrossRef]
  26. Matsuzaki, K. Control of cell selectivity of antimicrobial peptides. Biochim. Biophys. Acta (BBA)-Biomembr. 2009, 1788, 1687–1692. [Google Scholar] [CrossRef]
  27. Liu, L.; Liu, J.; Cui, Q.; Jia, B.-Y.; Pei, Z.-H.; Odah, K.A.; Wang, Y.-M.; Dong, W.-L.; Kong, L.-C.; Ma, H.-X. Design and Characterization of a Novel Hybrid Antimicrobial Peptide OM19R Based on Oncocin and MDAP-2. Int. J. Pept. Res. Ther. 2020, 26, 1839–1846. [Google Scholar] [CrossRef]
  28. Rahman, M.S.; Choi, Y.H.; Choi, Y.S.; Yoo, J.C. Glycin-rich antimicrobial peptide YD1 from B. amyloliquefaciens, induced morphological alteration in and showed affinity for plasmid DNA of E. coli. AMB Express 2017, 7, 8. [Google Scholar] [CrossRef]
  29. Chongsiriwatana, N.P.; Barron, A.E. Comparing Bacterial Membrane Interactions of Antimicrobial Peptides and Their Mimics. In Antimicrobial Peptides: Methods and Protocols; Human Press: Totowa, NJ, USA, 2010; pp. 171–182. [Google Scholar]
  30. Li, Y.; Liu, T.; Liu, Y.; Tan, Z.; Ju, Y.; Yang, Y.; Dong, W. Antimicrobial activity, membrane interaction and stability of the D-amino acid substituted analogs of antimicrobial peptide W3R6. J. Photochem. Photobiol. B 2019, 200, 111645. [Google Scholar] [CrossRef]
  31. Halder, A.; Karmakar, S. An evidence of pores in phospholipid membrane induced by an antimicrobial peptide NK-2. Biophys. Chem. 2022, 282, 106759. [Google Scholar] [CrossRef] [PubMed]
  32. Ebbensgaard, A.; Mordhorst, H.; Overgaard, M.T.; Nielsen, C.G.; Aarestrup, F.M.; Hansen, E.B. Comparative Evaluation of the Antimicrobial Activity of Different Antimicrobial Peptides against a Range of Pathogenic Bacteria. PLoS ONE 2015, 10, e0144611. [Google Scholar] [CrossRef]
  33. Lee, T.H.; Hall, K.N.; Aguilar, M.I. Antimicrobial peptide structure and mechanism of action: A focus on the role of membrane structure. Curr. Top. Med. Chem. 2016, 16, 25–39. [Google Scholar] [CrossRef]
  34. Moore, R.A.; Bates, N.C.; Hancock, R.E. Interaction of polycationic antibiotics with Pseudomonas aeruginosa lipopolysaccharide and lipid A studied by using dansyl-polymyxin. Antimicrob. Agents Chemother. 1986, 29, 496–500. [Google Scholar] [CrossRef] [PubMed]
  35. Espeche, J.C.; Varas, R.; Maturana, P.; Cutro, A.C.; Maffía, P.C.; Hollmann, A. Membrane permeability and antimicrobial peptides: Much more than just making a hole. Pept. Sci. 2023, e24305. [Google Scholar] [CrossRef]
  36. Lee, J.-K.; Seo, C.H.; Luchian, T.; Park, Y. Antimicrobial Peptide CMA3 Derived from the CA-MA Hybrid Peptide: Antibacterial and Anti-inflammatory Activities with Low Cytotoxicity and Mechanism of Action in Escherichia coli. Antimicrob. Agents Chemother. 2016, 60, 495–506. [Google Scholar] [CrossRef] [PubMed]
  37. Ciumac, D.; Gong, H.; Hu, X.; Lu, J.R. Membrane targeting cationic antimicrobial peptides. Curr. Opin. Colloid Interface Sci. 2019, 537, 163–185. [Google Scholar] [CrossRef]
  38. Lin, L.; Chi, J.; Yan, Y.; Luo, R.; Feng, X.; Zheng, Y.; Xian, D.; Li, X.; Quan, G.; Liu, D.; et al. Membrane-disruptive peptides/peptidomimetics-based therapeutics: Promising systems to combat bacteria and cancer in the drug-resistant era. Acta Pharm. Sin. B 2021, 11, 2609–2644. [Google Scholar] [CrossRef] [PubMed]
  39. Buck, A.K.; Elmore, D.E.; Darling, L.E. Using fluorescence microscopy to shed light on the mechanisms of antimicrobial peptides. Future Med. Chem. 2019, 11, 2447–2460. [Google Scholar] [CrossRef]
  40. Horrevoets, A.J.G.; Francke, C.; Verheij, H.M.; Haas, G.H. Activation of reconstituted Escherichia coli outer-membrane phospholipase A by membrane-perturbing peptides results in an increased reactivity towards the affinity label hexadecanesulfonyl fluoride. Eur. J. Org. Biochem. 1991, 198, 255–261. [Google Scholar] [CrossRef]
  41. Ko, S.J.; Park, E.; Asandei, A.; Choi, J.-Y.; Lee, S.-C.; Seo, C.H.; Luchian, T.; Park, Y. Bee venom-derived antimicrobial peptide melectin has broad-spectrum potency, cell selectivity, and salt-resistant properties. Sci. Rep. 2020, 10, 10145. [Google Scholar] [CrossRef]
  42. Ma, L.; Ye, X.; Sun, P.; Xu, P.; Wang, L.; Liu, Z.; Huang, X.; Bai, Z.; Zhou, C. Antimicrobial and antibiofilm activity of the EeCentrocin 1 derived peptide EC1-17KV via membrane disruption. eBioMedicine 2020, 55, 102775. [Google Scholar] [CrossRef]
  43. Tian, M.; Wang, K.; Liang, Y.; Chai, J.; Wu, J.; Zhang, H.; Huang, X.; Chen, X.; Xu, X. The first Brevinin-1 antimicrobial peptide with LPS-neutralizing and anti-inflammatory activities in vitro and in vivo. Front. Microbiol. 2023, 14, 1102576. [Google Scholar] [CrossRef] [PubMed]
  44. Regmi, S.; Choi, Y.S.; Choi, Y.H.; Kim, Y.K.; Cho, S.S.; Yoo, J.C.; Suh, J.-W. Antimicrobial peptide from Bacillus subtilis CSB138: Characterization, killing kinetics, and synergistic potency. Int. Microbiol. 2017, 20, 43–53. [Google Scholar] [PubMed]
  45. Ko, S.J.; Kim, M.K.; Bang, J.K.; Seo, C.H.; Luchian, T.; Park, Y. Macropis fulvipes Venom component Macropin Exerts its Antibacterial and Anti-Biofilm Properties by Damaging the Plasma Membranes of Drug Resistant Bacteria. Sci. Rep. 2017, 7, 16580. [Google Scholar] [CrossRef] [PubMed]
  46. Ma, Z.; Wei, D.; Yan, P.; Zhu, X.; Shan, A.; Bi, Z. Characterization of cell selectivity, physiological stability and endotoxin neutralization capabilities of α-helix-based peptide amphiphiles. Biomaterials 2015, 52, 517–530. [Google Scholar] [CrossRef]
  47. Lyu, Y.; Yang, Y.; Lyu, X.; Dong, N.; Shan, A. Antimicrobial activity, improved cell selectivity and mode of action of short PMAP-36-derived peptides against bacteria and Candida. Sci. Rep. 2016, 6, 27258. [Google Scholar] [CrossRef] [PubMed]
  48. Kwon, J.Y.; Kim, M.K.; Mereuta, L.; Seo, C.H.; Luchian, T.; Park, Y. Mechanism of action of antimicrobial peptide P5 truncations against Pseudomonas aeruginosa and Staphylococcus aureus. AMB Express 2019, 9, 122. [Google Scholar] [CrossRef] [PubMed]
  49. Mayer, L.D.; Hope, M.J.; Cullis, P.R. Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim. Biophys. Acta (BBA)-Biomembr. 1986, 858, 161–168. [Google Scholar] [CrossRef]
  50. Pulido, D.; Moussaoui, M.; Andreu, D.; Nogués, M.V.; Torrent, M.; Boix, E. Antimicrobial Action and Cell Agglutination by the Eosinophil Cationic Protein Are Modulated by the Cell Wall Lipopolysaccharide Structure. Antimicrob. Agents Chemother. 2012, 56, 2378–2385. [Google Scholar] [CrossRef]
  51. Kong, D.; Hua, X.; Zhou, R.; Cui, J.; Wang, T.; Kong, F.; You, H.; Liu, X.; Adu-Amankwaah, J.; Guo, G.; et al. Antimicrobial and Anti-Inflammatory Activities of MAF-1-Derived Antimicrobial Peptide Mt6 and Its D-Enantiomer D-Mt6 against Acinetobacter baumannii by Targeting Cell Membranes and Lipopolysaccharide Interaction. Microbiol. Spectr. 2022, 10, e0131222. [Google Scholar] [CrossRef]
  52. Ried, C.; Wahl, C.; Miethke, T.; Wellnhofer, G.; Landgraf, C.; Schneider-Mergener, J.; Hoess, A. High Affinity Endotoxin-binding and Neutralizing Peptides Based on the Crystal Structure of Recombinant Limulus Anti-lipopolysaccharide Factor. J. Biol. Chem. 1996, 271, 28120–28127. [Google Scholar] [CrossRef]
  53. Ko, S.J.; Kang, N.H.; Kim, M.K.; Park, J.; Park, E.; Park, G.H.; Kang, T.W.; Park, J.B.; Yi, Y.E.; Jeon, S.H.; et al. Antibacterial and anti-biofilm activity, and mechanism of action of pleurocidin against drug-resistant Staphylococcus aureus. Microb. Pathog. 2019, 127, 70–78. [Google Scholar] [CrossRef] [PubMed]
  54. Han, H.M.; Gopal, R.; Park, Y. Design and membrane-disruption mechanism of charge-enriched AMPs exhibiting cell selectivity, high-salt resistance, and anti-biofilm properties. Amino Acids 2015, 48, 505–522. [Google Scholar] [CrossRef]
  55. Amado, C.M.; Minahk, C.; Cilli, E.; Oliveira, R.G.; Dupuy, F.G. Bacteriocin enterocin CRL35 is a modular peptide that induces non-bilayer states in bacterial model membranes. Biochim. Biophys. Acta (BBA)-Biomembr. 2020, 1862, 183135. [Google Scholar] [CrossRef] [PubMed]
  56. Hernández-Ledesma, B.; Hsieh, C.-C.; de Lumen, B.O. Antioxidant and anti-inflammatory properties of cancer preventive peptide lunasin in RAW 264.7 macrophages. Biochem. Biophys. Res. Commun. 2009, 390, 803–808. [Google Scholar] [CrossRef] [PubMed]
Ijms 24 13522 g001
Figure 1. The synergistic effect of peptide YS12 with oxacillin against (a) E. coli KCTC 1923 (b) P. aeruginosa KCTC 1637. The time-killing effect of the combination of 2 × MIC (12 µg/mL) of peptide YS12 with 2 × MIC (96 µg/mL) oxacillin against E. coli and 2 × MIC (24 µg/mL) of peptide YS12 with 2 × MIC (48 µg/mL) oxacillin against P. aeruginosa was compared with the effect of 2 × MIC of peptide YS12, 2 × MIC of oxacillin alone, or untreated control.
Figure 1. The synergistic effect of peptide YS12 with oxacillin against (a) E. coli KCTC 1923 (b) P. aeruginosa KCTC 1637. The time-killing effect of the combination of 2 × MIC (12 µg/mL) of peptide YS12 with 2 × MIC (96 µg/mL) oxacillin against E. coli and 2 × MIC (24 µg/mL) of peptide YS12 with 2 × MIC (48 µg/mL) oxacillin against P. aeruginosa was compared with the effect of 2 × MIC of peptide YS12, 2 × MIC of oxacillin alone, or untreated control.
Ijms 24 13522 g001
Ijms 24 13522 g002
Figure 2. (a) Cell viability using Raw 264.7 cells was measured. Raw 264.7 cells were treated with peptide YS12 (5–120 µg/mL). (b) The hemolytic activity of peptide YS12 and Melittin with different concentrations (5–150 µg/mL) was determined. Each bar represents the mean ± SV obtained from three independent experiments, each performed in triplicate.
Figure 2. (a) Cell viability using Raw 264.7 cells was measured. Raw 264.7 cells were treated with peptide YS12 (5–120 µg/mL). (b) The hemolytic activity of peptide YS12 and Melittin with different concentrations (5–150 µg/mL) was determined. Each bar represents the mean ± SV obtained from three independent experiments, each performed in triplicate.
Ijms 24 13522 g002
Ijms 24 13522 g003
Figure 3. (a) Aggregation of large unilamellar vesicles (LUV). A quantity of 400 µM LUV with PE: PG (7:3, w/w) PG and PC were added to a solution containing different ratios of peptide YS12, and aggregation was observed at 405 nm. (b) E. coli cell survival was checked after treatment with lipopolysaccharide (LPS) either itself or in combination with ampicillin (10 µg/mL), polymyxin (5 µg/mL), and peptide (25 µg/mL).
Figure 3. (a) Aggregation of large unilamellar vesicles (LUV). A quantity of 400 µM LUV with PE: PG (7:3, w/w) PG and PC were added to a solution containing different ratios of peptide YS12, and aggregation was observed at 405 nm. (b) E. coli cell survival was checked after treatment with lipopolysaccharide (LPS) either itself or in combination with ampicillin (10 µg/mL), polymyxin (5 µg/mL), and peptide (25 µg/mL).
Ijms 24 13522 g003
Ijms 24 13522 g004
Figure 4. (a) Binding affinity of peptide for LPS (from E. coli) as analyzed using dansyl PMB. (b) LPS neutralization by peptide YS12 was determined using an endotoxin quantification kit.
Figure 4. (a) Binding affinity of peptide for LPS (from E. coli) as analyzed using dansyl PMB. (b) LPS neutralization by peptide YS12 was determined using an endotoxin quantification kit.
Ijms 24 13522 g004
Ijms 24 13522 g005
Figure 5. The potential antimicrobial mechanism on the bacterial membrane. PI uptake assay for membrane integrity of bacteria (a) E. coli ATCC 1923, (b) S. aureus KCTC 1928. (c) Release of cytoplasmic B-galactose of E. coli ATCC 1923 treated with peptide YS12 at different concentrations (1×, 2×, and 4 × MIC). (d) The calcein release rate treated with peptide YS12 was determined. 0.1% TritonX-100 was used as a positive control.
Figure 5. The potential antimicrobial mechanism on the bacterial membrane. PI uptake assay for membrane integrity of bacteria (a) E. coli ATCC 1923, (b) S. aureus KCTC 1928. (c) Release of cytoplasmic B-galactose of E. coli ATCC 1923 treated with peptide YS12 at different concentrations (1×, 2×, and 4 × MIC). (d) The calcein release rate treated with peptide YS12 was determined. 0.1% TritonX-100 was used as a positive control.
Ijms 24 13522 g005
Ijms 24 13522 g006
Figure 6. Localization of FITC-labeled peptide YS12 in bacterial cell membrane. (a) P. aeruginosa KCTC 1637 (b) E. coli. KCTC 1923 cells were incubated with peptide YS12 at the concentration of 4 × MIC. The bacterial cells were washed, fixed, and stained with DAPI (blue).
Figure 6. Localization of FITC-labeled peptide YS12 in bacterial cell membrane. (a) P. aeruginosa KCTC 1637 (b) E. coli. KCTC 1923 cells were incubated with peptide YS12 at the concentration of 4 × MIC. The bacterial cells were washed, fixed, and stained with DAPI (blue).
Ijms 24 13522 g006
Ijms 24 13522 g007
Figure 7. Effects of peptide YS12 on inhibiting proinflammatory cytokines including TNF-α, IL-1β, and NO. (a) The amount of NO was measured by Griess reagent in a concentration-dependent manner. (b) The effect of peptide YS12 was determined on cytokines including TNF-α, and (c) IL-1β. Each bar represents the mean ± SV of three independent trials.
Figure 7. Effects of peptide YS12 on inhibiting proinflammatory cytokines including TNF-α, IL-1β, and NO. (a) The amount of NO was measured by Griess reagent in a concentration-dependent manner. (b) The effect of peptide YS12 was determined on cytokines including TNF-α, and (c) IL-1β. Each bar represents the mean ± SV of three independent trials.
Ijms 24 13522 g007
Table 1. The MIC of peptide YS12 and antibiotics against bacterial strains.
Table 1. The MIC of peptide YS12 and antibiotics against bacterial strains.
MicroorganismsPeptide YS12 and AntibioticsMIC (µg/mL)
YS126
Oxacillin48
Escherichia coli KCTC 1923Ciprofloxacin12
Erythromycin48
YS1212
Oxacillin24
Pseudomonas aeruginosa KCTC 1637Ciprofloxacin48
Erythromycin>96
YS1248
Oxacillin>96
Staphylococcus aureus KCTC 1928Ciprofloxacin96
Erythromycin24
Table 2. The FIC index of peptide YS12 and antibiotics.
Table 2. The FIC index of peptide YS12 and antibiotics.
Bacterial StrainsPeptide-YS12 OxacillinPeptide-YS12 CiprofloxacinPeptide-YS12 Erythromycin
ΣFICInterpretationΣFICInterpretationΣFICInterpretation
Gram-negative
E. coli KCTC 19230.325Synergism0.157Synergism0.451Synergism
P. aeruginosa KCTC 16370.501Synergism0.749Partial synergism1.00Partial synergism
Gram-positive
S. aureus KCTC 19280.931Partial synergism0.75Partial synergism0.415Synergism
FIC of <0.5 was interpreted as synergism and 0.5 < 1.0 as an additive or partial synergism.
Table 3. Antimicrobial activity of peptide YS12 in the presence of different physiological salts.
Table 3. Antimicrobial activity of peptide YS12 in the presence of different physiological salts.
NaCl (mM)MgCl2 (mM)FeCl3 (µM)
Control 1001500.5124
E. coli KCTC 1923
peptide YS122228222
Melittin4424422
P. aeruginosa KCTC 1637
Peptide YS122224222
Melittin2222244
S. aureus ATCC 1928
Peptide YS124224222
Melittin4244242
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Suchi, S.A.; Lee, D.Y.; Kim, Y.K.; Kang, S.S.; Bilkis, T.; Yoo, J.C. Synergistic Effect, Improved Cell Selectivity, and Elucidating the Action Mechanism of Antimicrobial Peptide YS12. Int. J. Mol. Sci. 2023, 24, 13522. https://doi.org/10.3390/ijms241713522

AMA Style

Suchi SA, Lee DY, Kim YK, Kang SS, Bilkis T, Yoo JC. Synergistic Effect, Improved Cell Selectivity, and Elucidating the Action Mechanism of Antimicrobial Peptide YS12. International Journal of Molecular Sciences. 2023; 24(17):13522. https://doi.org/10.3390/ijms241713522

Chicago/Turabian Style

Suchi, Suzia Aktar, Dae Young Lee, Young Kyun Kim, Seong Soo Kang, Tahmina Bilkis, and Jin Cheol Yoo. 2023. "Synergistic Effect, Improved Cell Selectivity, and Elucidating the Action Mechanism of Antimicrobial Peptide YS12" International Journal of Molecular Sciences 24, no. 17: 13522. https://doi.org/10.3390/ijms241713522

APA Style

Suchi, S. A., Lee, D. Y., Kim, Y. K., Kang, S. S., Bilkis, T., & Yoo, J. C. (2023). Synergistic Effect, Improved Cell Selectivity, and Elucidating the Action Mechanism of Antimicrobial Peptide YS12. International Journal of Molecular Sciences, 24(17), 13522. https://doi.org/10.3390/ijms241713522

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop